FDA Approves POMALIDOMIDE — Dr. Reddy's Laboratories Inc.

Dr. Reddy’s Laboratories Inc. has received FDA approval for its ANDA213234, granting market exclusivity to its oral generic version of pomalidomide starting August 31, 2026. This regulatory clearance expands generic accessibility for this pivotal oncology treatment, positioning Dr. Reddy’s to capture further revenue in the increasingly competitive marketplace.